Literature DB >> 24620953

The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis.

Nazlıhan Boyacı, Gulbin Aygencel, Melda Turkoglu, Zeynep Arzu Yegin, Kadir Acar, Gulsan Turkoz Sucak.   

Abstract

OBJECTIVES: Hematopoietic stem cell transplantation (HSCT) recipients may require further management in intensive care unit (ICU). The ICU outcome of the HSCT recipients is claimed to have improved significantly over the last two decades. Our aim was to investigate the ICU outcome of the HSCT recipients who required management in ICU, together with the factors that are likely to affect the results.
MATERIALS AND METHODS: We retrospectively investigated the ICU outcome of 48 adults (≥18 years of age) who received HSCT in the bone marrow transplant unit of our hospital and required admission to ICU between 01 January 2007 and 31 December 2010. The data were retrieved from the databases of the adult bone marrow transplantation unit and the ICU.
RESULTS: Sixty-one percent of the patients were male with a median age of 39 years (28-46.75) in the study cohort. Leukemia (54%) and lymphoma (27%) were the leading underlying disorders. The type of HSCT was autologous in 14.6% and allogeneic in 85.4% of the patients. The reason for admission to ICU was acute respiratory failure in 85.5% of the HSCT recipients and 75% had sepsis/septic shock. The mean duration of ICU stay was 104.5 (48-168) hours. Sixty-nine percent of the patients died during their ICU stay while 31% survived. Besides the several statistically significant differences between the patients who survived or died in ICU in univariate analysis, baseline Acute Physiology and Chronic Health Evaluation (APACHE II) score (odds ratio 1.38, 95% confidence interval: 1.06-1.79) and requirement of vasopressors in the ICU (odds ratio 72.29, 95% confidence interval:4.47-1169.91) were found to be independent risk factors for mortality in multivariate analysis.
CONCLUSION: Baseline APACHE II score and requirement of vasopressors during ICU stay were the most significant independent risk factors for mortality in HSCT recipients who required ICU management in our center.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Intensive care unit; Mortality; Risk factors

Mesh:

Year:  2014        PMID: 24620953     DOI: 10.1179/1607845413Y.0000000130

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  7 in total

Review 1.  Intensive care outcomes in adult hematopoietic stem cell transplantation patients.

Authors:  Ulas D Bayraktar; Joseph L Nates
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  Management of Acute Respiratory Failure in Patients With Hematological Malignancy.

Authors:  Rakesh Vadde; Stephen M Pastores
Journal:  J Intensive Care Med       Date:  2016-07-07       Impact factor: 3.510

Review 3.  Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

Authors:  C Saillard; D Blaise; D Mokart
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 4.  A systematic review of prognostic factors at the end of life for people with a hematological malignancy.

Authors:  Elise Button; Raymond Javan Chan; Shirley Chambers; Jason Butler; Patsy Yates
Journal:  BMC Cancer       Date:  2017-03-23       Impact factor: 4.430

5.  Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014.

Authors:  Burkhard Dasch; Helen Kalies; Berend Feddersen; Caecilie Ruderer; Wolfgang Hiddemann; Claudia Bausewein
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

6.  Predictors of Poor Outcomes in Critically Ill Adults with Hematologic Malignancy.

Authors:  Marion Cornish; Michael B Butler; Robert S Green
Journal:  Can Respir J       Date:  2016-02-24       Impact factor: 2.409

7.  Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization.

Authors:  Christian S Michel; Daniel Teschner; Irene Schmidtmann; Matthias Theobald; Beate Hauptrock; Eva M Wagner-Drouet; Markus P Radsak
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.